Stem cell transplant with C-CAR088 CAR-T cells for ultra high-risk multiple myeloma
Tests a stem cell transplant with CAR-T cells in adults with aggressive myeloma.
Plain-language title generated from the registry record
Registry title: ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05632380, who can take part
Where in China
- Institute of Hematology & Blood Diseases HospitalTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT05632380
- Record updated
- 7 August 2026
- Original description
This is a phase I/II, single-arm, open-lable study of autologous stem cell transplantation in combination with C-CAR088, an autologous BCMA CAR-T cell product, for patients with ulta high-risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features.Read full original descriptionShow less
The Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Combination With C-CAR088, an Autologous BCMA CAR-T Cell Product, for Treating Patients With Ultra High-risk Multiple Myeloma
This is a phase I/II, single-arm, open-lable study of autologous stem cell transplantation in combination with C-CAR088, an autologous BCMA CAR-T cell product, for patients with ulta high-risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features.
Inclusion: Transplantation eligible patients, male or female, aged 18 to 70 years; Ultra high risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features; Adequate liver, renal, bone marrow, and heart function; Eastern Cooperative Oncology Group (ECOG) Performance status 0-1; Male and female of reproductive potential must agree to use birth control during the study.
Exclusion: Prior allogenic HSCT, or ASCT; Stroke or convulsion history within 6 months prior to signing ICF; Inadequate wash-out time for previous anti-tumor treatments prior to apheresis; Previous CAR-T cell treatment, genetically modified T-cell therapies or BCMA-directed treatment history; Known allergies to the components or excipients of the C-CAR088 cell product; Autoimmune disease, immunodeficiency or disease requiring immunosuppressants treatment; Uncontrolled active infection; active HBV, HCV infection; HIV or syphilis Infection; Severe heart, liver, renal or metabolism disease; History or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial; CNS involvement.